Skip to content

The effect of pentoxifylline mouthwash in the treatment of oral mucositis

Pentoxifylline mounthwash in the treatment of chemotherapy-induced mucositis; a randomized double blinded placebo-controlled clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180722040556N9
Enrollment
80
Registered
2022-05-07
Start date
2022-04-21
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced mucositis. Oral mucositis (ulcerative)

Interventions

Intervention 1: Intervention group: The research student, in collaboration with the doctors involved in the project, regularly inspects the internal departments of oncology, and if he sees a qualified

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: All adult patients (18 years and older) who refer to the inpatient ward of Seyed Al-Shohada Hospital for their treatment at the scheduled time) and develop oral mucositis during treatment. All adult patients (18 years and older) who undergo bone marrow transplantation in the stem cell transplant department at Omid Hospital and develop oral mucositis during transplantation. Having any severity of oral ulcer according to Common Terminology Criteria for Adverse Events version 4.0 classification Have a maximum performance score of 0-2 based on the Eastern Cooperative Oncology Group performance status classification Patients who are expected to survive for more than three months. Patients who have no history of oral and salivary gland diseases.

Exclusion criteria

Exclusion criteria: Patients who have a known allergy to pentoxifylline or any of the excipients used in the oral formulation. Patients who have participated in another ongoing clinical trial unless at least 4 weeks have elapsed since participating in the previous study. Patients with chronic use of steroids or immunosuppressive drugs. Patients who simultaneously have any acute or chronic progressive inflammatory oral disease.

Design outcomes

Primary

MeasureTime frame
Mouth dryness. Timepoint: One week. Method of measurement: mouth dryness questionnaire (VAS).;Quality of life. Timepoint: one week. Method of measurement: modified Oral Mucositis Daily Questionnaire (modified OMDQ).;Pain severity. Timepoint: one week. Method of measurement: pain scale questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Moghaddas

Esfahan University of Medical Sciences

azadeh_moghaddas@yahoo.com+98 31 3792 7074

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026